Comments
Zydus Cadila has received approval for the US health regulator to market Tadalafil tablets used for the treatment of erectile dysfunction in the American market.
The company has received tentative approval from the US Food and Drug Administration (USFDA) to market Tadalafil tablets USP in the strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg, Zydus Cadila said in a statement today.
The drug is indicated for the treatment of erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia, it added.
The product would be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
The group now has now more than 170 approvals and so far filed over 310 abbreviated new drug applications (ANDAs) since the commencement of the filing process in 2003-04.
Shares of Cadila Healthcare, group’s listed entity, were trading up by 0.4 per cent at Rs 444.45 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.